71,675 Shares in Icon Plc $ICLR Purchased by Arvin Capital Management LP

Arvin Capital Management LP purchased a new stake in shares of Icon Plc (NASDAQ:ICLR) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 71,675 shares of the medical research company’s stock, valued at approximately $12,543,000. Icon accounts for 2.3% of Arvin Capital Management LP’s investment portfolio, making the stock its 16th largest holding. Arvin Capital Management LP owned about 0.09% of Icon at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Private Trust Co. NA increased its stake in shares of Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after buying an additional 94 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in Icon by 153.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 201 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Icon in the second quarter valued at $61,000. Pilgrim Partners Asia Pte Ltd purchased a new position in Icon during the 3rd quarter valued at $63,000. Finally, Geneos Wealth Management Inc. raised its holdings in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the topic of a number of research reports. Truist Financial reaffirmed a “hold” rating and set a $222.00 target price (down from $231.00) on shares of Icon in a research note on Thursday, January 8th. Barclays raised their price objective on shares of Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Bank of America reaffirmed an “underperform” rating and set a $75.00 price objective on shares of Icon in a research report on Thursday, February 12th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Finally, Leerink Partners restated a “market perform” rating and issued a $105.00 target price on shares of Icon in a research note on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $157.47.

Icon Stock Up 0.4%

ICLR stock opened at $108.70 on Wednesday. The business has a 50 day moving average of $156.54 and a 200 day moving average of $169.35. The firm has a market cap of $8.78 billion, a PE ratio of 14.71, a price-to-earnings-growth ratio of 2.77 and a beta of 1.35. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.